{"id":"lo2a-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Iris pigmentation changes"},{"rate":null,"effect":"Eyelash growth"},{"rate":null,"effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL5940488","moleculeType":null,"molecularWeight":"498.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LO2A is a prostaglandin analog that binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, increasing uveoscleral outflow of aqueous humor and reducing intraocular pressure. This mechanism helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension by lowering the primary risk factor for disease progression.","oneSentence":"LO2A eye drops reduce intraocular pressure by enhancing aqueous humor outflow through the trabecular meshwork and Schlemm's canal.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:52:45.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02804191","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis","status":"COMPLETED","sponsor":"Ocuwize LTD","startDate":"2016-07","conditions":"Conjunctivochalasis","enrollment":62},{"nctId":"NCT03319420","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome","status":"COMPLETED","sponsor":"Ocuwize LTD","startDate":"2018-03-29","conditions":"Dry Eye Due to Sjögren's Syndrome","enrollment":60},{"nctId":"NCT02810119","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis","status":"COMPLETED","sponsor":"Ocuwize LTD","startDate":"2016-11","conditions":"Conjunctivochalasis","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LO2A eye drops","genericName":"LO2A eye drops","companyName":"Ocuwize LTD","companyId":"ocuwize-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LO2A eye drops reduce intraocular pressure by enhancing aqueous humor outflow through the trabecular meshwork and Schlemm's canal. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}